Intelligence · Clinical Development
Pipeline search results
Programs matching “Astra” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 467 pipeline programs matching "Astra" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
D9440C00003
AstraZeneca AB
Healthy Volunteers, Renal Impairment and End Stage Kidney Disease
1 trial -
D9441C00001
AstraZeneca AB
Chronic Kidney disease, Atherosclerotic Cardiovascular Disease
1 trial -
D9441C00004
AstraZeneca AB
Cardiorenal disease
1 trial -
D9470C00001
AstraZeneca AB
CD123-Positive Hematological Malignancies: Module 1 focuses on R/R Acute Myeloid Leukemia and R/R Myelodysplastic Syndrome.
1 trial -
D9609C00001
AstraZeneca AB
Healthy Volunteers
1 trial -
D9640C00001
AstraZeneca AB
Rheumatoid Arthritis
1 trial -
D967JC00002
AstraZeneca AB
Metastatic Breast Cancer
1 trial -
D967YC00001
AstraZeneca AB
Advanced or metastatic non-squamous non-small lung cancer (mNSCLC) with human epidermal growth factor receptor 2 (HER2) overexpression (OE)
1 trial -
D9690C00007
AstraZeneca AB
Crohn's disease
1 trial -
D9723C00002
AstraZeneca AB
advanced solid malignancies
1 trial -
D9961C00001
AstraZeneca AB
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
1 trial -
Drug-AZD8931
AstraZeneca
Breast Neoplasm
1 trial -
First-in-Human trial of DS9051b in participants with advanced solid tumors
Daiichi Sankyo
Advanced or Metastatic Adrenocortical Carcinoma (ACC), Metastatic Castration-resistant Prostate Cancer (CRPC)
1 trial -
JNJ-56021927
Janssen Cilag International NV
Prostatic Neoplasms, Castration-Resistant
1 trial -
LENVIMA hard capsules for Advanced Renal Cell Carcinoma
AstraZeneca AB
Advanced Renal Cell Carcinoma
1 trial -
M24-742
AbbVie Deutschland GmbH & Co. KG
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer
1 trial -
NKTR-214 (Cohort A)
INOVIO PHARMACEUTICALS, INC.
Metastatic Castration-resistant Prostate Cancer
1 trial -
PRIMROSE D9970C00001
AstraZeneca AB
Advanced/metastatic solid tumors that are MTAP deficient.
1 trial -
Phase 1 trial of valemetostat and darolutamide in mCRPC
Daiichi Sankyo
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1 trial -
Sodium Zirconium Cyclosilicate (ZS)
AstraZeneca
Hyperkalemia
1 trial -
TVB-2640
Sagimet Biosciences
Prostatic Neoplasms, Castration-Resistant
1 trial -
[225Ac]Ac-AKY-2519 (therapeutic)
Aktis Oncology
Castration Resistant Metastatic Prostate Cancer
1 trial -
illuccix 68Ga-PSMA-11 Total Body PET-CT
Telix Innovations
Metastatic Castration-resistant Prostate Cancer
1 trial -
20510
Bayer AG
metastatic castrate resistant prostate cancer (mCRPC)
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.